<![CDATA[Camizestrant Combo Misses PFS End Point in First-Line ER+/HER2– Breast Cancer]]>

Phase 3negativeCamizestrantPalbociclibAnastrozoleNegative

AI Analysis

Summary

Camizestrant combined with palbociclib failed to significantly improve progression-free survival compared to anastrozole/palbociclib in the phase 3 SERENA-4 trial for first-line ER+/HER2– breast cancer.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib

Importance:7/10

Sentiment:

-0.80

Phase 3Breast CancerER+/HER2–PFSFailed EndpointOncology

Related Companies

$TRAX

Read the original article

Published by Cancer Network on September 14, 2026 5:00 PM

Read Original